Abstract:Introduction and aim The current SARS-CoV-2 Omicron variant is distinct, compared to parental SARS-CoV-2 and other variant of concern (VOC), in at least two notable extents: 1) is a master of immune evasion but maintains robust angiotensin-converting enzyme 2 (ACE2) binding; and 2) depends more on cell endocytic pathway than other VOC to promote cell entry, leading to significant loss of endogenous mucosal ACE2 for lung protection as well as escape from neutralization antibodies and thus higher infectivity. The Omicron variant is more likely than other VOCs to cause upper airway infection and affects much less in lung distal tissue. People with weakened immune systems and those who had underlying conditions are considered high risk. Taken together the Omicron variant underscores the urgency of exploring effective prophylactic and therapeutic interventions to boost mucosal immunity against Omicron cell entry in upper airways. The study is to offer the potential prophylactic and therapeutic strategies protecting mucosal immunity against breakthrough infections. Patients and methods Based on the viral structure and the mechanisms of its interaction with host cells, we are testing several potential strategies against SARS-CoV-2 infection and its VOC in human lung organoids and humanized mice. The approaches include, but not limited to, using decoy viral particles, decoy host receptors and blockage of host receptor complex, as well as targeting the SARS-CoV-2 conserved non-structured protein regions and interrupting viral genome from which VOC with mutative spike proteins may escape. Results We have observed significant preservation of mucosal ACE2, decreases in viral load, clinical manifestation scores, lung injury scores using recombinant human ACE2 in humanized mice infected with SARS-CoV-2. We also demonstrated a potential prophylactic role of recombinant ACE2 and SARS-CoV-2 varus-like particles as decoys to attenuate the numbers of viral gene copy and cytopathic effects in human lung organoids infected with Delta and Omicron (BA.2) variants. Conclusion The decoy host receptor and decoy virus-like particles have shown promising results that will preserve mucosal host immunity and facilitate the development of effective prophylactic and treatment capability against breakthrough SARS-CoV-2 infections. Grant acknowledgement This work was supported by the Canadian Institutes of Health Research (OV3–170344, SBC-171482 and VS1–175560) to HZ.

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients

Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

COVID-19 neutralizing antibodies predict disease severity and survival

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

Seasonal Coronaviruses and SARS-CoV-2: Effects of Preexisting Immunity During the COVID-19 Pandemic

Early cross-coronavirus reactive signatures of humoral immunity against COVID-19

SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms

Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members

SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43

Protecting mucosal innate immunity against SARS-CoV-2 variant of concern

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses

Cross protection to SARS-CoV-2 variants in hamsters with naturally-acquired immunity

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

Spatiotemporal observations of host-pathogen interactions in mucosa during SARS-CoV-2 infection indicate a protective role of ILC2s